Metsera, Inc.
MTSR
Pozycja w akcjach
#2572
Metsera, Inc. operates as a clinical-stage biotechnology firm, specializing in... Metsera, Inc. operates as a clinical-stage biotechnology firm, specializing in crafting both injectable and oral nutrient-stimulated hormone analog peptides. These therapeutic compounds are primarily aimed at addressing obesity, overweight conditions, and associated health issues. Its developmental pipeline features MET-097i and MET-233i, both under investigation for treating obesity and overweight patients. Furthermore, Metsera is advancing a potential combination therapy involving MET-233i and MET-097i. The company is also progressing additional drug candidates, including MET-002, MET-224o, MET-067i, and MET-034i, all of which target disorders such as diabetes and obesity. Founded in 2022, Metsera, Inc. maintains its corporate headquarters in New York, New York.
Cena akcji
$70.50
Ostatnia synchronizacja: 2025-11-14
Kapitalizacja rynkowa
$7.33B
Zmiana (1 dzień)
0.00%
Zmiana (1 rok)
33.60%
Kraj
US
Handel Metsera, Inc. (MTSR)
Kategoria
Healthcare
Historia stopy dywidendy dla Metsera, Inc. (MTSR)
Stopa dywidendy (TTM) dla Metsera, Inc. (symbol akcji: MTSR) na dzień 2026 wynosi: 0
Średnia stopa dywidendy z ostatnich 5 lat: 0.00%
Średnia stopa dywidendy z ostatnich 5 lat: 0.00%
Historia stopy dywidendy dla Metsera, Inc. (MTSR) od 2023 do 2026
Stopa dywidendy na koniec każdego roku (TTM)
| Rok | Stopa dywidendy | Zmień |
|---|---|---|
| 2024 | 0.00% | 0.00% |
| 2023 | 0.00% | 0.00% |
Stopy dywidendy (TTM) dla podobnych firm lub konkurencji
| Firma | Stopa dywidendy | Kraj |
|---|---|---|
| 0.00% |
US
|
|
| 0.00% |
US
|
|
| 2.17% |
AU
|
|
| 0.00% |
NL
|
|
| 0.00% |
CH
|
